OptiNose (OPTN) Stock Forecast, Price Target & Predictions
OPTN Stock Forecast
OptiNose stock forecast is as follows: an average price target of $1.00 (represents a 138.04% upside from OPTN’s last price of $0.42) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OPTN Price Target
OPTN Analyst Ratings
Buy
OptiNose Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 13, 2024 | David Amsellem | Piper Sandler | $1.00 | $0.89 | 12.36% | 138.04% |
May 15, 2024 | Thomas Flaten | Loop Capital Markets | $3.00 | $1.12 | 167.86% | 614.12% |
Nov 14, 2022 | BMO Capital | $5.00 | $2.01 | 148.76% | 1090.19% | |
Jun 13, 2022 | David Amsellem | Piper Sandler | $4.00 | $2.62 | 52.56% | 852.15% |
OptiNose Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $1.00 | $2.00 |
Last Closing Price | $0.42 | $0.42 | $0.42 |
Upside/Downside | -100.00% | 138.04% | 376.08% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
May 15, 2024 | Lake Street | Buy | Buy | Hold |
Aug 21, 2023 | Cowen & Co. | Outperform | Initialise | |
Aug 21, 2023 | Noble Capital Markets | Outperform | Initialise | |
Aug 21, 2023 | Lake Street | Buy | Initialise | |
Nov 14, 2022 | BMO Capital | Outperform | Outperform | Hold |
Jun 13, 2022 | Piper Sandler | Overweight | Overweight | Hold |
OptiNose Financial Forecast
OptiNose Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $19.86M | $19.82M | $19.45M | $11.85M | $20.86M | $20.08M | $20.58M | $14.76M | $22.51M | $21.83M | $18.36M | $11.96M | $16.35M | $15.44M | $10.27M | $7.06M | $11.08M | $12.40M | $6.68M | $4.48M | $865.00K |
Avg Forecast | $31.80M | $27.60M | $24.20M | $17.70M | $22.31M | $22.95M | $20.58M | $14.90M | $19.26M | $18.68M | $17.36M | $9.85M | $20.71M | $23.35M | $20.55M | $16.71M | $21.75M | $23.50M | $18.08M | $11.17M | $17.92M | $14.58M | $9.79M | $7.72M | $11.64M | $8.58M | $6.62M | $3.80M | $779.57K |
High Forecast | $33.92M | $29.44M | $25.82M | $18.88M | $25.28M | $22.98M | $20.58M | $15.90M | $20.55M | $18.68M | $18.52M | $10.51M | $22.10M | $23.35M | $20.55M | $16.71M | $21.75M | $23.50M | $18.08M | $11.17M | $17.92M | $14.58M | $9.79M | $7.72M | $11.64M | $8.58M | $6.62M | $3.80M | $935.48K |
Low Forecast | $30.53M | $26.50M | $23.23M | $16.99M | $20.75M | $22.93M | $20.58M | $14.30M | $18.49M | $18.68M | $16.67M | $9.46M | $19.88M | $23.35M | $20.55M | $16.71M | $21.75M | $23.50M | $18.08M | $11.17M | $17.92M | $14.58M | $9.79M | $7.72M | $11.64M | $8.58M | $6.62M | $3.80M | $623.65K |
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
Surprise % | - | - | - | - | - | - | - | - | 1.03% | 1.06% | 1.12% | 1.20% | 1.01% | 0.86% | 1.00% | 0.88% | 1.03% | 0.93% | 1.02% | 1.07% | 0.91% | 1.06% | 1.05% | 0.91% | 0.95% | 1.44% | 1.01% | 1.18% | 1.11% |
Forecast
OptiNose EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
EBITDA | - | - | - | - | - | - | - | - | $-4.95M | $-1.69M | $-4.17M | $-14.37M | $-8.36M | $-10.61M | $-15.17M | $-21.14M | $-11.44M | $-12.57M | $-19.33M | $-22.01M | $-19.94M | $-17.39M | $-22.30M | $-25.68M | $-22.29M | $-26.15M | $-24.66M | $-26.22M | $-28.22M |
Avg Forecast | $-24.50M | $-21.26M | $-18.64M | $-13.64M | $-17.19M | $-17.68M | $-15.86M | $-11.48M | $-14.84M | $-14.39M | $-13.38M | $-7.59M | $-15.96M | $-18.39M | $-16.18M | $-18.01M | $-17.13M | $-18.51M | $-14.24M | $-23.67M | $-14.11M | $-11.48M | $-7.71M | $-26.47M | $-9.17M | $-6.76M | $-5.21M | $-26.59M | $-25.13M |
High Forecast | $-23.52M | $-20.41M | $-17.90M | $-13.09M | $-15.99M | $-17.66M | $-15.86M | $-11.02M | $-14.25M | $-14.39M | $-12.84M | $-7.28M | $-15.32M | $-18.39M | $-16.18M | $-14.41M | $-17.13M | $-18.51M | $-14.24M | $-18.94M | $-14.11M | $-11.48M | $-7.71M | $-21.18M | $-9.17M | $-6.76M | $-5.21M | $-21.27M | $-20.10M |
Low Forecast | $-26.14M | $-22.68M | $-19.89M | $-14.55M | $-19.48M | $-17.70M | $-15.86M | $-12.25M | $-15.83M | $-14.39M | $-14.27M | $-8.10M | $-17.02M | $-18.39M | $-16.18M | $-21.61M | $-17.13M | $-18.51M | $-14.24M | $-28.41M | $-14.11M | $-11.48M | $-7.71M | $-31.77M | $-9.17M | $-6.76M | $-5.21M | $-31.90M | $-30.16M |
Surprise % | - | - | - | - | - | - | - | - | 0.33% | 0.12% | 0.31% | 1.89% | 0.52% | 0.58% | 0.94% | 1.17% | 0.67% | 0.68% | 1.36% | 0.93% | 1.41% | 1.51% | 2.89% | 0.97% | 2.43% | 3.87% | 4.73% | 0.99% | 1.12% |
Forecast
OptiNose Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
Net Income | - | - | - | - | - | - | - | - | $-10.16M | $-9.29M | $2.63M | $-18.65M | $-17.33M | $-14.95M | $-19.40M | $-25.33M | $-19.64M | $-17.12M | $-23.50M | $-26.05M | $-23.86M | $-21.21M | $-25.85M | $-28.86M | $-25.00M | $-28.81M | $-27.38M | $-28.87M | $-30.57M |
Avg Forecast | $3.49M | $-1.74M | $-5.23M | $-8.72M | $-8.22M | $-9.15M | $-13.49M | $-18.53M | $-15.21M | $-16.45M | $-18.92M | $-24.41M | $-30.47M | $-28.05M | $-36.54M | $-21.58M | $-39.18M | $-53.95M | $-62.79M | $-28.02M | $-69.57M | $-78.86M | $-84.39M | $-29.74M | $-93.43M | $-106.39M | $-110.91M | $-29.28M | $-27.22M |
High Forecast | $3.79M | $-1.65M | $-4.96M | $-8.27M | $-6.17M | $-8.68M | $-12.79M | $-17.56M | $-14.81M | $-15.60M | $-17.94M | $-23.14M | $-28.89M | $-28.05M | $-36.54M | $-17.26M | $-39.18M | $-53.95M | $-62.79M | $-22.42M | $-69.57M | $-78.86M | $-84.39M | $-23.80M | $-93.43M | $-106.39M | $-110.91M | $-23.42M | $-21.78M |
Low Forecast | $3.31M | $-1.90M | $-5.69M | $-9.48M | $-10.28M | $-9.95M | $-14.66M | $-20.14M | $-15.60M | $-17.88M | $-20.57M | $-26.53M | $-33.12M | $-28.05M | $-36.54M | $-25.90M | $-39.18M | $-53.95M | $-62.79M | $-33.62M | $-69.57M | $-78.86M | $-84.39M | $-35.69M | $-93.43M | $-106.39M | $-110.91M | $-35.14M | $-32.67M |
Surprise % | - | - | - | - | - | - | - | - | 0.67% | 0.56% | -0.14% | 0.76% | 0.57% | 0.53% | 0.53% | 1.17% | 0.50% | 0.32% | 0.37% | 0.93% | 0.34% | 0.27% | 0.31% | 0.97% | 0.27% | 0.27% | 0.25% | 0.99% | 1.12% |
Forecast
OptiNose SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
SG&A | - | - | - | - | - | - | - | - | $18.96M | $18.01M | $20.10M | $22.72M | $23.31M | $25.49M | $29.51M | $29.34M | $26.34M | $25.80M | $27.31M | $27.18M | $28.11M | $24.57M | $25.70M | $27.06M | $26.55M | $25.27M | $26.00M | $26.34M | $27.82M |
Avg Forecast | $57.99M | $50.33M | $44.13M | $32.28M | $40.68M | $41.86M | $37.53M | $27.17M | $35.13M | $34.07M | $31.66M | $17.96M | $37.77M | $42.56M | $37.45M | $30.45M | $39.64M | $42.83M | $32.95M | $20.35M | $32.66M | $26.57M | $17.85M | $14.07M | $21.21M | $15.64M | $12.06M | $6.93M | $1.42M |
High Forecast | $61.86M | $53.69M | $47.08M | $34.43M | $46.11M | $41.90M | $37.53M | $28.99M | $37.48M | $34.07M | $33.77M | $19.16M | $40.30M | $42.56M | $37.45M | $30.45M | $39.64M | $42.83M | $32.95M | $20.35M | $32.66M | $26.57M | $17.85M | $14.07M | $21.21M | $15.64M | $12.06M | $6.93M | $1.70M |
Low Forecast | $55.67M | $48.32M | $42.37M | $30.99M | $37.84M | $41.81M | $37.53M | $26.09M | $33.72M | $34.07M | $30.39M | $17.24M | $36.26M | $42.56M | $37.45M | $30.45M | $39.64M | $42.83M | $32.95M | $20.35M | $32.66M | $26.57M | $17.85M | $14.07M | $21.21M | $15.64M | $12.06M | $6.93M | $1.14M |
Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.53% | 0.64% | 1.27% | 0.62% | 0.60% | 0.79% | 0.96% | 0.66% | 0.60% | 0.83% | 1.34% | 0.86% | 0.92% | 1.44% | 1.92% | 1.25% | 1.62% | 2.16% | 3.80% | 19.58% |
Forecast
OptiNose EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.08 | - | $-0.17 | $-0.18 | $-0.18 | $-0.23 | $-0.31 | $-0.29 | $-0.32 | $-0.44 | $-0.49 | $-0.46 | $-0.43 | $-0.56 | $-0.63 | $-0.58 | $-0.69 | $-0.66 | $-0.70 | $-0.81 |
Avg Forecast | $0.02 | $-0.01 | $-0.03 | $-0.05 | $-0.05 | $-0.05 | $-0.08 | $-0.11 | $-0.09 | $-0.09 | $-0.11 | $-0.14 | $-0.17 | $-0.19 | $-0.24 | $-0.27 | $-0.26 | $-0.36 | $-0.42 | $-0.53 | $-0.46 | $-0.52 | $-0.56 | $-0.66 | $-0.62 | $-0.71 | $-0.74 | $-0.71 | $-0.65 |
High Forecast | $0.02 | $-0.01 | $-0.03 | $-0.05 | $-0.04 | $-0.05 | $-0.07 | $-0.10 | $-0.08 | $-0.09 | $-0.10 | $-0.13 | $-0.17 | $-0.19 | $-0.24 | $-0.27 | $-0.26 | $-0.36 | $-0.42 | $-0.53 | $-0.46 | $-0.52 | $-0.56 | $-0.66 | $-0.62 | $-0.71 | $-0.74 | $-0.71 | $-0.52 |
Low Forecast | $0.02 | $-0.01 | $-0.03 | $-0.05 | $-0.06 | $-0.06 | $-0.08 | $-0.12 | $-0.09 | $-0.10 | $-0.12 | $-0.15 | $-0.19 | $-0.19 | $-0.24 | $-0.27 | $-0.26 | $-0.36 | $-0.42 | $-0.53 | $-0.46 | $-0.52 | $-0.56 | $-0.66 | $-0.62 | $-0.71 | $-0.74 | $-0.71 | $-0.78 |
Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.88% | - | 1.21% | 1.03% | 0.97% | 0.95% | 1.15% | 1.12% | 0.89% | 1.06% | 0.92% | 1.00% | 0.82% | 1.00% | 0.96% | 0.94% | 0.98% | 0.90% | 0.98% | 1.25% |
Forecast
OptiNose Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
KMDA | Kamada | $5.75 | $20.00 | 247.83% | |
PROC | Procaps Group | $3.69 | $10.00 | 171.00% | |
IRWD | Ironwood Pharmaceuticals | $3.53 | $8.50 | 140.79% | Buy |
DVAX | Dynavax | $12.90 | $29.00 | 124.81% | Buy |
OPTN | OptiNose | $0.46 | $1.00 | 117.39% | Buy |
EOLS | Evolus | $11.73 | $24.00 | 104.60% | Buy |
AMPH | Amphastar Pharmaceuticals | $40.85 | $66.00 | 61.57% | Buy |
ANIP | ANI Pharmaceuticals | $55.83 | $79.00 | 41.50% | Buy |
COLL | Collegium Pharmaceutical | $30.90 | $42.33 | 36.99% | Buy |
ALKS | Alkermes | $30.75 | $37.50 | 21.95% | Hold |
NBIX | Neurocrine Biosciences | $136.69 | $156.14 | 14.23% | Buy |
PBH | Prestige Consumer Healthcare | $80.39 | $89.50 | 11.33% | Buy |
ITCI | Intra-Cellular Therapies | $86.96 | $93.33 | 7.33% | Buy |
LFCR | Lifecore Biomedical | $7.47 | $6.50 | -12.99% | Buy |
PAHC | Phibro Animal Health | $22.34 | $18.67 | -16.43% | Buy |